DEA Locks Down Seven Sneaky Fentanyl Cousins in Schedule I
Published Date: 9/18/2025
Rule
Summary
The DEA is officially putting seven specific fentanyl-related substances into Schedule I, meaning they’re now treated as very dangerous drugs with strict rules. This affects anyone who makes, sells, studies, or even holds these substances, who must follow tough laws and face serious penalties if they don’t. These changes take effect right away, aiming to keep communities safer and stop illegal use.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
Seven Fentanyl-Related Drugs Now Schedule I
The DEA officially placed seven specified fentanyl-related substances (including their isomers, esters, ethers, and salts) into Schedule I under the Controlled Substances Act. That means anyone who manufactures, distributes, imports, exports, possesses, or handles these substances is now subject to the full regulatory controls and criminal, civil, and administrative sanctions that apply to Schedule I drugs.
Research and Instruction Now Covered by Schedule I Rules
The rule explicitly subjects research, instructional activities, and chemical analysis involving these seven fentanyl-related substances to Schedule I controls. If you study or teach about these substances or run chemical analyses, you must now follow Schedule I requirements for handling and possession.
Regulation Aims to Improve Community Safety
The DEA states the action is intended to keep communities safer and stop illegal use by treating these seven fentanyl-related substances as Schedule I drugs. The change is effective immediately to strengthen enforcement and controls.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-18094 — Safety Zone; San Pedro Bay, Long Beach, CA
The Coast Guard is setting up a temporary safety zone around Port of Long Beach Berth G232 and first-responder boats to keep everyone safe from floating shipping containers. No boats or people can enter these zones unless the Captain of the Port says it’s okay. This helps protect workers, vessels, and the environment during cleanup efforts.
Next: 2025-18149 — Standard Instrument Approach Procedures, and Takeoff Minimums and Obstacle Departure Procedures; Miscellaneous Amendments
This update changes some airport approach and takeoff rules to keep flights safe and smooth. It affects pilots flying in certain airports by updating how they land and take off, based on new tech and obstacles. These changes start soon and help everyone fly smarter without extra costs.